Previous Article | Next Article 
Journal of Virology, January 2004, p. 513-519, Vol. 78, No. 1
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.1.513-519.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Chromosome-Protein Interactions in Polyomavirus Virions
Mariarosaria Carbone,1 Giuseppe Ascione,1 Silvia Chichiarelli,2 Marie-Isabelle Garcia,1 Margherita Eufemi,2 and Paolo Amati1*
Dipartimento di Biotecnologie Cellulari ed Ematologia, Sezione di Genetica Molecolare,1
Dipartimento di Scienze Biochimiche "A. Rossi Fanelli," Università di Roma "La Sapienza," 00161 Rome, Italy2
Received 23 June 2003/
Accepted 17 September 2003

ABSTRACT
In this work, we sought to determine whether the components
of the murine polyomavirus capsid establish specific interactions
with the minichromosome encapsidated into the mature viral particles
by using the
cis-diamminedichloroplatinum(II) cross-linking
reagent. Our data indicated that VP1, but not minor capsid proteins,
interacts with the viral genome in vivo. In addition, semiquantitative
PCR assays performed on cross-linked DNA complexes revealed
that VP1 binds to all regions of the viral genome but significantly
more to the regulatory region. The implications of such an interaction
for viral infectivity are discussed.

TEXT
The murine polyomavirus (Py) genome is organized into a minichromosome
that is formed from a supercoiled circular double-stranded 5.3-kb
DNA molecule with which cellular histones are associated (
15).
This chromatin is encapsidated into an icosahedral capsid composed
of 72 pentamers of the major capsid protein VP1, with each pentamer
being associated with minor capsid protein VP2 or VP3 (
15).
Several functions in the lytic life cycle, other than the structural
one, have been assigned to the capsid proteins. The VP1 protein
mediates the initial attachment and entry into host cells through
interaction with sialic acids and integrins (
2,
8,
20,
42,
43),
and VP2 has been proposed to participate in viral cell entry
(
11,
28,
39). In addition, previous characterizations of Py
mutants of the VP1 DE loop have also suggested a role for VP1
in viral growth control (
22,
29,
38). Indeed, at early times
postinfection, VP1 appears to colocalize with the infecting
viral minichromosome in the cell nucleus and, in particular,
at the nuclear matrix (NM), where viral transcription and replication
take place (
5,
10,
14). The finding that VP1 interacts with
the NM regulatory protein YY1 early after infection suggests
that VP1 may be required to anchor viral genomes to the NM for
the formation of protein complexes that are necessary for early
transcription (
35). In accordance with this hypothesis, previous
reports aimed at studying the potential interactions between
capsid proteins and DNA have demonstrated that VP1, but not
the minor coat proteins, is able to bind DNA through a DNA-binding
domain (DBD) mapped within its first seven N-terminal residues
(
9,
31). These experiments were performed with an in vitro method
and thus did not allow the attribution of any DNA sequence specificity
to the DBD of VP1, as VP1 binds all Py and non-Py DNA sequences
with equivalent high affinities (
9,
31). The aim of the present
work was to determine whether the components of the Py capsid
establish interactions with the minichromosome encapsidated
into the mature viral particles and, if so, with what specificity.
For this purpose, we decided to treat mature Py virions with
the
cis-diamminedichloroplatinum(II) (
cis-DDP) reagent, a molecule
that produces inter- and intra-DNA strand cross-links independently
of the sequence (
6,
25,
37) and preferentially induces cross-links
between DNA and nonhistone proteins located within a distance
of 4 Å (
16,
27). In contrast to formaldehyde,
cis-DDP
does not form protein-protein complexes (
40). Furthermore, with
respect to other cross-linking agents such as UV, the cross-linking
reaction promoted by
cis-DDP is fully reversible and allows
for the recovery and characterization of the cross-linked proteins
and DNA sequences (
7,
17,
30,
32).
cis-DDP cross-links viral DNA in virions.
To set up the experimental conditions, mature viral particles or a control naked DNA (Py genome cloned into plasmid pAT153 [22]) was incubated with different concentrations (25, 35, and 50 µM) of cis-DDP (Sigma) for 90 min at 37°C. The efficiency of cross-linking was first tested by analyzing the ability of the DNA that was extracted from the cross-linked samples to be hybridized in Southern blot experiments with the Py genome used as the probe (22). Quantification of the hybridization efficiency was performed with an Instant-Imager. As shown in Fig. 1A, the cis-DDP reagent reduced the hybridization efficiency of both the control naked DNA and the encapsidated minichromosome in a dose-dependent manner (with a maximum of 35%), indicating that the drug had penetrated the viral particles and cross-linked the viral DNA. The same kind of results were obtained by PCR analysis when DNA extracted from cross-linked samples was used as the template; this DNA appeared less amplified than that extracted from non-cross-linked samples (data not shown). Next, to isolate cross-linked DNA complexes and to test which drug concentration was the most appropriate to recover them with the highest efficiency, viral particles (approximately 5 µg of VP1) treated with different cis-DDP concentrations were dissociated with 10 mM EDTA and 3 mM dithiothreitol and separated on a denaturing gradient composed of 0.5% Sarkosyl and 1.42 g of CsCl/cm3 by ultracentrifugation (35,000 rpm for 72 h [Optima LE-80K ultracentrifuge; Beckman Coulter]) (34). This type of denaturing gradient abolishes the interactions between DNA and non-cross-linked proteins and fully disassembles nucleosomes (34). Free DNA would be expected to sediment at a density of
1.65 g/cm3, whereas DNA-protein complexes should sediment in fractions of lower density. We analyzed the distribution of viral DNA in the gradient with a slot blot experiment by hybridizing an equal volume (1/30) of each fraction with the whole Py genome as a probe. As anticipated, in both cis-DDP-treated and untreated samples, free DNA sedimented at a density of
1.65 g/cm3 (Fig. 1B). Additionally, two types of signals were detected at lower densities in cis-DDP-treated virions at all of the concentrations used (Table 1). In fractions with densities of 1.32 to 1.34 g/cm3, signals increased with drug concentrations and represented up to 18.2% of total DNA at 50 µM (67% of the cross-linked DNA). The signal corresponded to stabilized, undissociated viral particles as confirmed by electron microscopy (data not shown). In addition, another signal that was detected at densities of 1.56 to 1.60 g/cm3 (hypothesized to contain DNA-protein complexes) appeared consistently more intense in virions that were treated with 35 µM cis-DDP than in those that were treated with 25 µM cis-DDP or left untreated (16.2% versus 3.38 and 0.38% of total DNA, respectively). But higher drug concentrations (50 µM cis-DDP) resulted in reduced viral dissociation (Table 1) due to a further stabilization of undissociated virions and consequently decreased the recovery of DNA-protein complexes (8.62% of total DNA versus 16.2% at 35 µM). Therefore, the next experiments were performed with the intermediate concentration of cis-DDP (35 µM).
VP1, but not VP2 or VP3, binds viral DNA.
In order to determine if Py capsid proteins bind to the genome
in the mature particles, the presence of these proteins in cross-linked
DNA complexes was examined as follows. The same viral preparation
was divided into two samples: one was treated with
cis-DDP (35
µM), and the other was left untreated. Then, viral particles
were dissociated and loaded onto a denaturing CsCl gradient
as described above. After centrifugation, fractions were analyzed
for both Py DNA (see above) and capsid proteins by slot blotting
by using anti-VP1 or anti-VP2/3 antisera (
18). The distribution
of VP1 and VP2/3 in the gradient was revealed by using horseradish
peroxidase-conjugated secondary anti-mouse immunoglobulin G
and an enhanced chemiluminescence reaction (Pierce) and was
then quantified by densitometry (ImageMaster 2D Elite; Pharmacia
Biotech). As shown in Fig.
2A and B, different patterns of distribution
of the VP1 protein were found in
cis-DDP-treated and -untreated
samples. Indeed, whereas under both experimental conditions
the VP1 protein was detected mainly in the lower-density fractions,
in
cis-DDP-treated samples, a strong signal (arbitrary units,
an approximate 25-fold increase with respect to
cis-DDP-untreated
samples) was evidenced in the fractions of higher density (1.56
to 1.60 g/cm
3) that were presumed to contain cross-linked DNA
complexes. In contrast, the distributions of the VP2/3 proteins
were very similar in
cis-DDP-treated and -untreated samples,
i.e., the minor capsid proteins were detected in the lowest-density
fractions (1.20 to 1.28 g/cm
3), but no signal at all could be
detected in the higher-density fractions (1.56 to 1.60 g/cm
3)
(Fig.
2A). In fractions corresponding to the undissociated virions
(density, 1.32 to 1.34 g/cm
3), VP2/3 proteins were found exclusively
in the
cis-DDP-treated samples. These data suggest that VP1,
but not the minor proteins, is associated with the viral genome
in mature virions. To confirm this hypothesis, fractions from
cis-DDP-treated or -untreated samples with buoyant densities
of 1.56 to 1.60 g/cm
3 were pooled, dialyzed against a Tris-EDTA
buffer to remove CsCl, and then subjected to immunoprecipitation
with anti-VP1 antibodies or without antibodies (as a control)
in a radioimmunoprecipitation assay buffer (
36). Immunoprecipitated
and immunodepleted samples were treated with 1.5 M thiourea
(Sigma) to reverse cross-links, digested with proteinase K,
and extracted with phenol-chloroform. The presence of viral
DNA in the extracted samples was assessed by PCR with primer
pairs specific for the Py genome (see Fig.
4A) as follows. The
PCR buffer was comprised of 1
x Taq polymerase buffer (Promega),
3 mM MgCl
2, 0.3 mM each deoxynucleoside triphosphate (Roche),
0.5 U of
Taq polymerase (Promega), and 0.5 pmol of each primer/µl,
and the PCR was carried out for 30 cycles of 92°C for 30
s, 50°C for 1 min, and 74°C for 2 min. The initial cycle
had a denaturation step of 3 min at 94°C. As shown in Fig.
2C, in a representative PCR assay performed with primer pair
9, only anti-VP1-immunoprecipitated samples from
cis-DDP-treated
virions gave an amplification signal, confirming the physical
association between VP1 and the viral minichromosome.
Analysis of the viral DNA sequences cross-linked to Py VP1.
We next investigated whether viral DNA that was cross-linked
to VP1 had any sequence specificity. Since
cis-DDP modifies
some bases, rendering impossible the use of DNA endonucleases
(
4) to fragment DNA, viral genomes were broken mechanically
by sonication. We first determined the time that was necessary
to induce homogeneous DNA fragmentation. Viral particles treated
with
cis-DDP were divided into equal volumes and sonicated for
10, 20, 30, 60, or 90 s (amplitude, 80). Cross-links were reversed,
and DNA was extracted for Southern blot analysis. The results
of hybridization which were quantified with an Instant-Imager
indicated that 10, 20, or 30 s was not long enough to obtain
a complete fragmentation. Instead, 60 s was sufficient to give
rise to DNA fragments ranging from 250 to 660 bp (mean, approximately
430 bp), while a longer sonication time (90 s) did not significantly
reduce the size of fragments and only increased variability
(data not shown). Therefore, a sonication time of 60 s was chosen
for our analysis. Then, to characterize the cross-linked viral
DNA sequences, the DNA from fractions at buoyant densities of
1.56 to 1.60 g/cm
3 was sonicated, immunoprecipitated with anti-VP1
antibodies, and used as a template in semiquantitative differential
PCRs. This method relies on the coamplification of both the
Py target sequence (variable amount) and a reference sequence
(fixed amount) in the same reaction vessel (
21). Equal volumes
of the immunoprecipitated samples, which were designated the
target sequences, were coamplified with the pLITMUS plasmid
(New England Biolabs), which was used as the reference sequence.
pLITMUS sequences were amplified with the primers corresponding
to nucleotides (nt) 2095 to 2112 (forward) and nt 2660 to 2645
(reverse). The PCRs were performed as described above in the
presence of 10
6 cpm of [

-
32P]dATP (NEN Life Science Products,
Boston, Mass.). Twelve primer pairs were designated to cover
all of the viral genome and to amplify segments of approximately
300 bp (see Fig.
4A) with a similar annealing temperature. PCR
products were electrophoresed on 7% nondenaturing polyacrylamide
gels; the gels were fixed and dried, and the bands were quantified.
The choice of 10
7 molecules per tube as a fixed amount of reference
sequence was determined in preliminary PCRs in which increasing
amounts of the target sequence were used (Fig.
3A, left panel).
The ratio of amplification of the Py and pLITMUS sequences appeared
as a function of the initial amount of the template Py sequence,
thus validating our calculation method (Fig.
3A, right panel).
The results of representative experiments obtained with primer
pairs 4 and 8 are shown in Fig.
3B (left and right panels, respectively),
and results obtained with all of the primer pairs are reported
in Fig.
4 . To take into consideration any potential differential
efficiency of amplification among primer pairs, the amplification
value was calculated for each primer pair as the ratio (Py/ref)
IP/[(Py/ref)
IP + (Py/ref)
ID], where Py is the target sequence, ref is the reference
sequence, IP is immunoprecipitation, and ID is immunodepletion.
The finding that all the primer pairs that were tested on VP1-immunoprecipitated
complexes gave positive amplification signals indicated that
VP1 is associated with all segments of the Py genome. Some viral
regions appeared to be more abundantly represented among the
complexes. However, the region encompassing the enhancer, the
origin of replication, and the early and late promoters and
their transcription start sites (nt 4900 to 190) was found to
be 1.8-fold more amplified than the nonregulatory region. These
results suggest that Py VP1 is associated with the entire Py
genome but significantly more with the control region.
Conclusions.
Previous reports have analyzed the structural features of the
Py and simian virus 40 (SV40) minichromosomes as model systems
for studying eukaryotic gene structure-function relationships.
These studies were done with viral genomes that were extracted
from infected cells before encapsidation (70S) and capsid assembly
intermediates (180S) but not with the mature virions (240S)
(
12). In this work, we used the
cis-DDP reagent to cross-link
intact murine Py particles in order to analyze the potential
interactions between the minichromosome and the proteins (histones
excluded) present in viral particles. We found that VP1 interacts
with the viral genome but that the minor coat proteins VP2 and
VP3 do not. In addition, at a level of sensitivity of 100 pg,
no other nonhistone proteins that were associated with viral
DNA could be detected (data not shown). Our data are in accord
with previous in vitro experiments that have mapped the DBD
of VP1 to the N terminus, a disordered region predicted by crystallography
to be oriented internally towards the minichromosome core (
9,
31,
44). Although the affinity of the VP1-DNA interaction could
not be measured by the present method, this association appeared
to be very strong. In fact, we could detect the VP1-DNA complexes
in un-cross-linked samples at very low levels in the radiolabeled
semiquantitative PCR assays (Fig.
3B, right panel). The present
work has demonstrated that, in mature viral particles, VP1 interacts
with all regions of the genome. Such a broad association may
suggest that VP1 plays a structural role in the protection of
the encapsidated DNA from the extracellular medium. This hypothesis
seems to be sustained by the observation that the fixation of
the DNA-VP1 interactions with
cis-DDP generates totally stabilized
and undissociated viral particles. In the related virus SV40,
such a role has also been proposed, and mutations in the DBD
of the VP1 are indeed associated with altered virion formation
and viability (
26). In addition, VP1 may contribute to modulating
or maintaining the chromatin compaction of the encapsidated
viral DNA, promoted initially by the linker histone H1 once
it is displaced from the minichromosome during the final maturation
of viral particles (
45). The other finding of this report is
that the viral sequences extending over the regulatory region
(i.e., the origin of replication, the enhancer, and early and
late promoters) are 60 to 80% more highly represented in the
sonication fragments that were immunoprecipitated with anti-VP1
antibodies than in the sonicated fragments covering the coding
Py sequences. We found that the VP1-rich region was quite large
(approximately 1,200 bp), but this may be ascribed in part to
the size of the sonication fragments (mean, 430 bp) used for
the PCR assays. This region is the one described earlier as
nucleosome free in viral genomes extracted from infected cells,
which correspond to the 70S chromatin form (
13,
23). For SV40,
a comparative analysis of the nucleosome spacing of minichromosomes
showed an increase in length distribution of nucleosomes in
assembly intermediates of 180S with respect to the preencapsidated
chromatin of 70S, suggesting the nucleosome redistribution of
the nucleosome-free region during encapsidation (
12). In addition,
studies of SV40 temperature-sensitive mutants have led to the
proposal that VP1 has a role in this process (
1,
3). Our present
data show that VP1 is preferentially associated with this particular
region of the Py genome. Although we cannot conclude that nucleosomes
are totally absent in the VP1-rich region, our data certainly
indicate that this region has greater accessibility by VP1 for
interaction than does the rest of the genome. We propose that
the binding of VP1 to this region represents more of a structural
preference than a sequence-specific interaction with the regulatory
region, which is consistent with studies performed in vitro
with murine Py and SV40 that failed to detect any sequence preference
for the VP1 interaction with viral DNA (
9,
31,
41). In contrast
to SV40 (
33), no specific encapsidation initiation site has
been reported for the Py genome. We suggest that the binding
of VP1 to the noncoding region is used as the signal for the
encapsidation of murine viral DNA. Furthermore, since it is
well known that the accessibility of regulatory factors by chromatin
conditions gene expression, it is likely that the preferential
association of VP1 with the regulatory region may have a role
in the initial phases of viral infection. Indeed, previous evidence
has shown that VP1 may be required to control viral expression
and to anchor viral genomes to the NM through interactions with
NM factors such as YY1 (
35). The higher (and/or stronger) association
of VP1 with the enhancer region may favor the binding of host
factors to this region by influencing the nucleosome organization
and may consequently influence viral gene transcription. In
addition, a direct role in the formation of the complexes necessary
for early transcription is also possible for VP1 that is bound
to the enhancer region. This hypothesis is supported by the
previous observation that
cis-dominant mutations of VP1 change
the Py host range and early transcription ability (
22,
29,
38).
Further cross-linking studies performed with infected cells
should help to identify qualitative and/or quantitative variations
in the association of VP1 with the viral genome before early
transcription occurs and therefore help to verify the hypothesized
multifunctional role of VP1 in the Py life cycle. It has been
demonstrated that Py capsids and pseudocapsids can transfer
heterologous DNA to mammalian cells but that this transfer is
quite inefficient (
19,
24). This may be due in part to an incorrect
chromatin structure of the cloned DNA associated with VP1. Therefore,
a better knowledge of the DNA-binding properties of VP1 during
the infectious process seems to be of primary interest for the
further improvement of pseudocapsid vehicles for gene transfer.

ACKNOWLEDGMENTS
We thank Massimo Gentile for electron microscopy analysis and
Carlo Turano, Rossella Maione, and Maddalena Caruso for useful
suggestions and critical discussions.
This work was supported by MIUR funds. Istituto Pasteur-Fondazione Cenci Bolognetti finances both departments.

FOOTNOTES
* Corresponding author. Mailing address: Dipartimento di Biotecnologie Cellulari ed Ematologia, Sezione di Genetica Molecolare, Università di Roma "La Sapienza," Viale Regina Elena 324, 00161 Rome, Italy. Phone: 3906490393. Fax: 39064462891. E-mail:
amati{at}bce.uniroma1.it.


REFERENCES
1 - Ambrose, C., V. Blasquez, and M. Bina. 1986. A block in initiation of simian virus 40 assembly results in the accumulation of minichromosomes containing an exposed regulatory region. Proc. Natl. Acad. Sci. USA 83:3287-3291.[Abstract/Free Full Text]
2 - Bauer, P. H., C. Cui, T. Stehle, S. C. Harrison, J. A. De Caprio, and T. L. Benjamin. 1999. Discrimination between sialic acid-containing receptors and pseudoreceptors regulates polyomavirus spread in the mouse. J. Virol. 73:5826-5832.[Abstract/Free Full Text]
3 - Blasquez, V., A. Stein, C. Ambrose, and M. Bina. 1986. Simian virus 40 protein VP1 is involved in spacing nucleosomes in minichromosomes. J. Mol. Biol. 191:97-106.[CrossRef][Medline]
4 - Brabec, V., and Z. Balcarova. 1993. Restriction-enzyme cleavage of DNA modified by platinum(II) complexes. Eur. J. Biochem. 216:183-187.[Medline]
5 - Buckler-White, A. J., G. W. Humphrey, and V. Pigiet. 1980. Association of polyoma T antigen and DNA with the nuclear matrix from lytically infected 3T6 cells. Cell 22:37-46.[CrossRef][Medline]
6 - Burstyn, J. N., W. J. Heiger-Bernays, S. M. Cohen, and S. J. Lippard. 2000. Formation of cis-diamminedichloroplatinum(II) 1, 2-intrastrand cross-links on DNA is flanking-sequence independent. Nucleic Acids Res. 28:4237-4243.[Abstract/Free Full Text]
7 - Carr, A., and M. D. Biggin. 1999. An in vivo UV crosslinking assay that detects DNA binding by sequence-specific transcription factors. Methods Mol. Biol. 119:497-508.[Medline]
8 - Caruso, M., L. Belloni, O. Sthandier, P. Amati, and M.-I. Garcia. 2003.
4ß1 integrin acts as a cell receptor for murine polyomavirus at the postattachment level. J. Virol. 77:3913-3921.[Abstract/Free Full Text]
9 - Chang, D., X. Cai, and R. A. Consigli. 1993. Characterization of the DNA binding properties of polyomavirus capsid proteins. J. Virol. 67:6327-6331.[Abstract/Free Full Text]
10 - Chen, L.-F., K. Ito, Y. Murakami, and Y. Ito. 1998. The capacity of polyomavirus enhancer binding protein 2
B (AML1/Cbfa2) to stimulate polyomavirus DNA replication is related to its affinity for the nuclear matrix. Mol. Cell. Biol. 18:4165-4176.[Abstract/Free Full Text]
11 - Chen, X. S., T. Stehle, and S. C. Harrison. 1998. Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. EMBO J. 17:3233-3240.[CrossRef][Medline]
12 - Coca-Prados, M., H. Y.-H. Yu, and M.-T. Hsu. 1982. Intracellular forms of simian virus 40 nucleoprotein complexes. IV. Micrococcal nuclease digestion. J. Virol. 44:603-609.[Abstract/Free Full Text]
13 - Cremisi, C., P. F. Pignatti, O. Croissant, and M. Yaniv. 1976. Chromatin-like structures in polyoma virus and simian virus 40 lytic cycle. J. Virol. 17:204-211.[Abstract/Free Full Text]
14 - Deppert, W., and R. Schirmbeck. 1995. The nuclear matrix and virus function. Int. Rev. Cytol. 162:485-537.
15 - Eckhart, W. 1990. Polyomavirinae and their replication, p. 1593-1607. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology. Raven, New York, N.Y.
16 - Filipski, J., K. W. Kohn, and W. M. Bonner. 1983. Differential crosslinking of histones and non-histones in nuclei by cis-Pt(II). FEBS Lett. 152:105-108.[CrossRef][Medline]
17 - Filipski, J., K. W. Kohn, R. Prather, and W. M. Bonner. 1979. Thiourea reverses cross-links and restores biological activity in DNA treated with dichlorodiaminoplatinum(II). Science 204:181-183.[Abstract/Free Full Text]
18 - Forstová, J., N. Krauzewicz, S. Wallace, A. J. Street, S. M. Dilworth, S. Beard, and B. E. Griffin. 1993. Cooperation of structural proteins during late events in the life cycle of polyomavirus. J. Virol. 67:1405-1413.[Abstract/Free Full Text]
19 - Forstovà, J., N. Krauzewicz, V. Sandig, J. Elliott, Z. Palkovà, M. Strauss, and B. E. Griffin. 1995. Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells. Hum. Gene Ther. 6:297-306.[Medline]
20 - Fried, H., L. D. Cahan, and J. C. Paulson. 1981. Polyoma virus recognizes specific sialyligosaccharide receptors on host cells. Virology 109:188-192.[CrossRef][Medline]
21 - Frye, R. A., C. C. Benz, and E. Liu. 1989. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 4:1153-1157.[Medline]
22 - Garcia, M. I., M. Perez, M. Caruso, O. Sthandier, R. Ferreira, M. Cermola, C. Macchia, and P. Amati. 2000. A mutation in the DE loop of the VP1 protein that prevents polyomavirus transcription and replication. Virology 272:293-301.[CrossRef][Medline]
23 - Jakobovits, E. B., S. Bratosin, and Y. Aloni. 1980. A nucleosome-free region in SV40 minichromosomes. Nature 285:263-265.[CrossRef][Medline]
24 - Krauzewicz, N., and B. E. Griffin. 2000. Polyoma and papilloma virus vectors for cancer gene therapy. Adv. Exp. Med. Biol. 465:73-82.[Medline]
25 - Lemaire, M. A., A. Schwartz, A. R. Rahmouni, and M. Leng. 1991. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc. Natl. Acad. Sci. USA 88:1982-1985.[Abstract/Free Full Text]
26 - Li, P. P., A. Nakanishi, D. Shum, P. C.-K. Sun, A. M. Salazar, C. F. Fernandez, S.-W. Chan, and H. Kasamatsu. 2001. Simian virus 40 Vp1 DNA-binding domain is functionally separable from the overlapping nuclear localization signal and is required for effective virion formation and full viability. J. Virol. 75:7321-7329.[Abstract/Free Full Text]
27 - Lippard, S. J., and J. D. Hoeschele. 1979. Binding of cis- and trans-dichlorodiammineplatinum(II) to the nucleosome core. Proc. Natl. Acad. Sci. USA 76:6091-6095.[Abstract/Free Full Text]
28 - Mannova, P., D. Liebl, N. Krauzewicz, A. Fejtova, J. Stokrova, Z. Palkova, B. E. Griffin, and J. Forstovà. 2002. Analysis of mouse polyomavirus mutants with lesions in the minor capsid proteins. J. Gen. Virol. 83:2309-2319.[Abstract/Free Full Text]
29 - Mezes, B., and P. Amati. 1994. Mutations of polyomavirus VP1 allow in vitro growth in undifferentiated cells and modify in vivo tissue replication specificity. J. Virol. 68:1196-1199.[Abstract/Free Full Text]
30 - Micetich, K., L. A. Zwelling, and K. W. Kohn. 1983. Quenching of DNA:platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells. Cancer Res. 43:3609-3613.[Abstract/Free Full Text]
31 - Moreland, R. B., L. Montross, and R. L. Garcea. 1991. Characterization of the DNA-binding properties of the polyomavirus capsid protein VP1. J. Virol. 65:1168-1176.[Abstract/Free Full Text]
32 - Olinski, R., A. Wedrychowski, W. N. Schmidt, R. C. Briggs, and L. S. Hnilica. 1987. In vivo DNA-protein cross-linking by cis- and trans-diamminedichloroplatinum(II). Cancer Res. 47:201-205.[Abstract/Free Full Text]
33 - Oppenheim, A., Z. Sandalon, A. Peleg, O. Shaul, S. Nicolis, and S. Ottolenghi. 1992. A cis-acting DNA signal for encapsidation of simian virus 40. J. Virol. 66:5320-5328.[Abstract/Free Full Text]
34 - Orlando, V., and R. Paro. 1993. Mapping Polycomb-repressed domains in the bithorax complex using in vivo formaldehyde cross-linked chromatin. Cell 75:1187-1198.[CrossRef][Medline]
35 - Palková, Z., D. Hollanderová, V. Gottifredi, H.
panielová, J. Forstová, and P. Amati. 2000. The polyomavirus major capsid protein VP1 interacts with the host nuclear matrix regulatory protein YY1. FEBS Lett. 467:359-364.[CrossRef][Medline]
36 - Pelicci, G., L. Lanfrancone, A. E. Salcini, A. Romano, S. Mele, M. Grazia Borrello, O. Segatto, P. P. Di Fiore, and P. G. Pelicci. 1995. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 11:899-907.[Medline]
37 - Pinto, A. L., and S. J. Lippard. 1985. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta 780:167-180.[Medline]
38 - Ricci, L., R. Maione, C. Passananti, A. Felsani, and P. Amati. 1992. Mutations in the VP1 coding region of polyomavirus determine differentiating stage specificity. J. Virol. 66:7153-7158.[Abstract/Free Full Text]
39 - Sahli, R., R. Freund, T. Dubensky, R. L. Garcea, R. Bronson, and T. L. Benjamin. 1993. Defect in entry and altered pathogenicity of a polyoma virus mutant blocked in VP2 myristylation. Virology 192:142-153.[CrossRef][Medline]
40 - Solomon, M. J., and A. Varshavsky. 1985. Formaldehyde-mediated DNA-protein crosslinking: a probe for in vivo chromatin structures. Proc. Natl. Acad. Sci. USA 82:6470-6474.[Abstract/Free Full Text]
41 - Soussi, T. 1986. DNA-binding properties of the major structural protein of simian virus 40. J. Virol. 59:740-742.[Abstract/Free Full Text]
42 - Stehle, T., Y. Yan, T. L. Benjamin, and S. C. Harrison. 1994. Structure of polyomavirus complexed with an oligosaccharide receptor fragment. Nature 369:160-163.[CrossRef][Medline]
43 - Stehle, T., and S. C. Harrison. 1997. High-resolution structure of a polyomavirus VP1-oligosaccharide complex: implications for assembly and receptor binding. EMBO J. 16:5139-5148.[CrossRef][Medline]
44 - Yan, Y., T. Stehle, R. C. Liddington, H. Zhao, and S. C. Harrison. 1996. Structure determination of simian virus 40 and murine polyomavirus by a combination of 30-fold and 5-fold electron-density averaging. Structure 4:157-164.[Medline]
45 - Yuen, L. K., and R. A. Consigli. 1985. Identification and protein analysis of polyomavirus assembly intermediates from infected primary mouse embryo cells. Virology 144:127-138.[CrossRef][Medline]
Journal of Virology, January 2004, p. 513-519, Vol. 78, No. 1
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.1.513-519.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.